Literature DB >> 28623450

The relationship between excitement symptom severity and extrastriatal dopamine D2/3 receptor availability in patients with schizophrenia: a high-resolution PET study with [18F]fallypride.

Yo-Han Joo1, Jeong-Hee Kim1,2, Young-Don Son1,3, Hang-Keun Kim1,3, Yeon-Jeong Shin1, Sang-Yoon Lee1,4, Jong-Hoon Kim5,6.   

Abstract

The purpose of this study was to investigate the relationship between specific symptom severity and D2/3 receptor availability in extrastriatal regions in outpatients with schizophrenia to shed light on the role of extrastriatal dopaminergic neurotransmission in the pathophysiology of symptoms of schizophrenia. Sixteen schizophrenia patients receiving relatively low-dose maintenance atypical antipsychotics and seventeen healthy controls underwent 3-Tesla magnetic resonance imaging and high-resolution positron emission tomography with [18F]fallypride. For D2/3 receptor availability, the binding potential with respect to non-displaceable compartment (BPND) was derived using the simplified reference tissue model. The BPND values were lower in patients on antipsychotic treatment than in controls across all regions with large effect sizes (1.03-1.42). The regions with the largest effect size were the substantia nigra, amygdala, and insula. Symptoms of schizophrenia were assessed using a five-factor model of the Positive and Negative Syndrome Scale (PANSS). The region of interest-based analysis showed that PANSS excitement factor score had a significant positive correlation with the [18F]fallypride BPND in the insula. The equivalent dose of antipsychotics was not significantly correlated with PANSS factor scores or regional BPND values. The voxel-based analysis also revealed a significant positive association between the PANSS excitement factor and the [18F]fallypride BPND in the insula. The present study revealed a significant association between excitement symptom severity and D2/3 receptor availability in the insula in schizophrenia, suggesting a possible important role of D2/3 receptor-mediated neurotransmission in the insula and related limbic system in the pathophysiology of this specific symptom cluster.

Entities:  

Keywords:  Excitement symptom; Extrastriatal D2/3 receptor; High-resolution PET; Insula; Schizophrenia; [18F]fallypride

Mesh:

Substances:

Year:  2017        PMID: 28623450     DOI: 10.1007/s00406-017-0821-y

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  64 in total

1.  Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT.

Authors:  Andrea Varrone; Nils Sjöholm; Lars Eriksson; Balazs Gulyás; Christer Halldin; Lars Farde
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-13       Impact factor: 9.236

2.  Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography.

Authors:  Lawrence S Kegeles; Mark Slifstein; Xiaoyan Xu; Nina Urban; Judy L Thompson; Tiffany Moadel; Jill M Harkavy-Friedman; Roberto Gil; Marc Laruelle; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2010-07-31       Impact factor: 13.382

3.  Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine.

Authors:  Robert M Kessler; M Sib Ansari; Patrizia Riccardi; Rui Li; Karuna Jayathilake; Benoit Dawant; Herbert Y Meltzer
Journal:  Neuropsychopharmacology       Date:  2006-05-31       Impact factor: 7.853

4.  Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia.

Authors:  Romina Mizrahi; Pablo Rusjan; Ofer Agid; Ariel Graff; David C Mamo; Robert B Zipursky; Shitij Kapur
Journal:  Am J Psychiatry       Date:  2007-04       Impact factor: 18.112

5.  Dual-isotope SPECT imaging of striatal dopamine: a comparative study between never-treated and haloperidol-treated first-episode schizophrenic patients.

Authors:  G J E Schmitt; S Dresel; T Frodl; C la Fougère; R Boerner; K Hahn; H-J Möller; E M Meisenzahl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11-13       Impact factor: 5.270

6.  Frontal dopamine D(2/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender.

Authors:  Birte Y Glenthoj; Torben Mackeprang; Claus Svarer; Hans Rasmussen; Lars H Pinborg; Lars Friberg; William Baaré; Ralf Hemmingsen; Charlotte Videbaek
Journal:  Biol Psychiatry       Date:  2006-04-03       Impact factor: 13.382

7.  Association between cognitive performance and striatal dopamine binding is higher in timing and motor tasks in patients with schizophrenia.

Authors:  Yen Kuang Yang; Tzung Lieh Yeh; Nan Tsing Chiu; I Hui Lee; Po See Chen; Li-Ching Lee; Keith J Jeffries
Journal:  Psychiatry Res       Date:  2004-09-15       Impact factor: 3.222

8.  Voxel-based analysis of 11C-PIB scans for diagnosing Alzheimer's disease.

Authors:  Arthur Mikhno; Davangere Devanand; Gregory Pelton; Katrina Cuasay; Roger Gunn; Neil Upton; Robert Y Lai; Vincenzo Libri; J John Mann; Ramin V Parsey
Journal:  J Nucl Med       Date:  2008-07-16       Impact factor: 10.057

9.  Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCR.

Authors:  Michael J Hurley; Deborah C Mash; Peter Jenner
Journal:  Eur J Neurosci       Date:  2003-11       Impact factor: 3.386

Review 10.  Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies.

Authors:  Joseph Kambeitz; Anissa Abi-Dargham; Shitij Kapur; Oliver D Howes
Journal:  Br J Psychiatry       Date:  2014-06       Impact factor: 9.319

View more
  4 in total

1.  QModeling: a Multiplatform, Easy-to-Use and Open-Source Toolbox for PET Kinetic Analysis.

Authors:  Francisco J López-González; José Paredes-Pacheco; Karl Thurnhofer-Hemsi; Carlos Rossi; Manuel Enciso; Daniel Toro-Flores; Belén Murcia-Casas; Antonio L Gutiérrez-Cardo; Núria Roé-Vellvé
Journal:  Neuroinformatics       Date:  2019-01

2.  Is schizophrenia still one entity with similar symptomatic patterns, neurobiological characteristics, and treatment perspectives?

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-09       Impact factor: 5.270

3.  Effects of a GWAS-Supported Schizophrenia Variant in the DRD2 Locus on Disease Risk, Anhedonia, and Prefrontal Cortical Thickness.

Authors:  Margarita V Alfimova; Nikolay V Kondratyev; Alexander S Tomyshev; Irina S Lebedeva; Tatyana V Lezheiko; Vasiliy G Kaleda; Lilia I Abramova; Vera E Golimbet
Journal:  J Mol Neurosci       Date:  2019-05-03       Impact factor: 3.444

Review 4.  Allosteric Interactions between Adenosine A2A and Dopamine D2 Receptors in Heteromeric Complexes: Biochemical and Pharmacological Characteristics, and Opportunities for PET Imaging.

Authors:  Kavya Prasad; Erik F J de Vries; Philip H Elsinga; Rudi A J O Dierckx; Aren van Waarde
Journal:  Int J Mol Sci       Date:  2021-02-09       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.